Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 16, 2026 is 231.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 217.11 % — a change of 6.85% (higher).

FCF Conversion

231.98 %

YoY

6.85%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Vcanbio Cell & Gene Engineering Corp is 2025 231.98 % . FCF Conversion Rate (FCF/EBITDA) of Vcanbio Cell & Gene Engineering Corp was 2024 217.11 % . It decreases by 6.85% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
3.29 CNY
Jan 1, 2019
238.53 CNY
Jan 1, 2020
-120.31 CNY
Jan 1, 2021
124.40 CNY
Jan 1, 2022
144.00 CNY
Jan 1, 2023
197.65 CNY
Jan 1, 2024
217.11 CNY
Jan 1, 2025
231.98 CNY
The Vcanbio Cell & Gene Engineering Corp FCF Conversion history
YEARFCF ConversionYoY
231.98 %+6.85%
217.11 %+9.85%
197.65 %+37.26%
144.00 %+15.76%
124.40 %-203.40%
-120.31 %-150.44%
238.53 %+7,152.58%
3.29 %-102.67%
-122.97 %-63.10%
-333.29 %+476.14%
-57.85 %-112.74%
453.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

FCF Conversion Rate (FCF/EBITDA) of Vcanbio Cell & Gene Engineering Corp is 231.98 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Vcanbio Cell & Gene Engineering Corp changed from 217.11 % to 231.98 %, representing a 6.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp